Literature DB >> 1799732

Technical considerations for myocardial protection during the course of coronary artery bypass reoperation: the impact of functioning saphenous vein and internal mammary artery grafts.

N L Mills1, C T Everson, D R Hockmuth.   

Abstract

New technical challenges involving the delivery of cardioplegia during the course of coronary artery bypass operation continue to be presented to the surgeon. Functioning saphenous grafts at reoperation that are at risk for distal embolization, are managed by altering the standard cardioplegia delivery techniques. Management of patent internal mammary artery (IMA) grafts depends upon the status of the native circulation and coronary collateral. The reoperation may be performed with a fibrillating heart, standard cardioplegia with a clamped mammary graft, or cardioplegia delivered during simultaneous circulatory arrest. Myocardial temperature measurements, during the course of more complex operations, are useful in choosing the appropriate technique for myocardial protection.

Entities:  

Mesh:

Year:  1991        PMID: 1799732     DOI: 10.1111/j.1540-8191.1991.tb00561.x

Source DB:  PubMed          Journal:  J Card Surg        ISSN: 0886-0440            Impact factor:   1.620


  3 in total

1.  Aortic Valve Replacement for Patients with Functioning Internal Mammalian Artery Grafts.

Authors:  Naoki Masaki; Takashi Ogasawara; Shun-Ichi Kawarai; Katsuo Matsuki
Journal:  Ann Thorac Cardiovasc Surg       Date:  2017-09-26       Impact factor: 1.520

2.  A patent internal mammary artery graft decreases the risk of reoperative coronary artery bypass surgery.

Authors:  V Velebit; J T Christenson; J Maurice; F Simonet; M Schmuziger
Journal:  Tex Heart Inst J       Date:  1994

3.  Aortic valve replacement after coronary artery bypass grafting with the in situ right gastroepiploic artery to the occluded right coronary artery using a temporary vein graft for cardioplegia.

Authors:  Yoshifumi Fuke; Toru Yasutsune; Masato Sakamoto
Journal:  Surg Case Rep       Date:  2017-04-24
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.